InMode [INMD] vs Abbott Laboratories [ABT] Detailed Stock Comparison
InMode
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: InMode wins in 12 metrics, Abbott Laboratories wins in 7 metrics, with 0 ties. InMode appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | InMode | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 5.91 | 16.43 | InMode |
| Price-to-Book Ratio | 1.42 | 4.51 | InMode |
| Debt-to-Equity Ratio | 0.97 | 26.50 | InMode |
| PEG Ratio | 6.64 | 25.37 | InMode |
| EV/EBITDA | 3.34 | 20.46 | InMode |
| Profit Margin (TTM) | 44.50% | 32.43% | InMode |
| Operating Margin (TTM) | 23.93% | 19.73% | InMode |
| EBITDA Margin (TTM) | 23.93% | 19.73% | InMode |
| Return on Equity | 25.91% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 9.14% | 6.62% | InMode |
| Free Cash Flow (TTM) | $132.00M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -13.28% | 21.53% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 2.21 | 5.29 | InMode |
| Enterprise Value | $385.38M | $234.33B | Abbott Laboratories |
| EV/Revenue Ratio | 0.96 | 5.44 | InMode |
| Gross Profit Margin (TTM) | 79.97% | 56.44% | InMode |
| Revenue per Share (TTM) | $6 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $2.38 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.93 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
InMode vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| InMode | -1.95% | 5.20% | -4.83% | 1.05% | -20.34% | -15.27% |
| Abbott Laboratories | 1.69% | 4.65% | -1.23% | -1.41% | 2.32% | 16.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| InMode | -13.28% | -62.20% | -11.29% | 99.43% | 99.43% | 99.43% |
| Abbott Laboratories | 21.53% | 18.51% | 32.13% | 163.03% | 450.04% | 491.67% |
Performance & Financial Health Analysis: InMode vs Abbott Laboratories
| Metric | INMD | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $889.35M | $227.88B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 1,222,050 | 5,718,390 |
| 90 Day Avg. Volume | 1,557,887 | 7,295,300 |
| Last Close | $14.09 | $134.29 |
| 52 Week Range | $13.14 - $19.85 | $107.11 - $141.23 |
| % from 52W High | -29.02% | -4.91% |
| All-Time High | $99.27 (Nov 01, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -85.81% | -5.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.07% |
| Quarterly Earnings Growth | 0.12% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.45% | 0.32% |
| Operating Margin (TTM) | 0.24% | 0.20% |
| Return on Equity (TTM) | 0.26% | 0.31% |
| Debt to Equity (MRQ) | 0.97 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.94 | $29.05 |
| Cash per Share (MRQ) | $8.07 | $4.18 |
| Operating Cash Flow (TTM) | $104.61M | $9.04B |
| Levered Free Cash Flow (TTM) | $39.67M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: InMode vs Abbott Laboratories
| Metric | INMD | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 5.91 | 16.43 |
| Forward P/E | 6.64 | 25.37 |
| PEG Ratio | 6.64 | 25.37 |
| Price to Sales (TTM) | 2.21 | 5.29 |
| Price to Book (MRQ) | 1.42 | 4.51 |
| Market Capitalization | ||
| Market Capitalization | $889.35M | $227.88B |
| Enterprise Value | $385.38M | $234.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.96 | 5.44 |
| Enterprise to EBITDA | 3.34 | 20.46 |
| Risk & Other Metrics | ||
| Beta | 1.93 | 0.71 |
| Book Value per Share (MRQ) | $9.94 | $29.05 |
Financial Statements Comparison: InMode vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | INMD | ABT |
|---|---|---|
| Revenue/Sales | $77.87M | $10.36B |
| Cost of Goods Sold | $16.96M | $4.47B |
| Gross Profit | $60.91M | $5.89B |
| Research & Development | $2.90M | $716.00M |
| Operating Income (EBIT) | $15.62M | $1.69B |
| EBITDA | $15.79M | $2.66B |
| Pre-Tax Income | $22.48M | $1.78B |
| Income Tax | $4.28M | $453.00M |
| Net Income (Profit) | $18.20M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | INMD | ABT |
|---|---|---|
| Cash & Equivalents | $145.95M | $6.53B |
| Total Current Assets | $634.64M | $23.15B |
| Total Current Liabilities | $72.66M | $13.00B |
| Long-Term Debt | $5.59M | $12.74B |
| Total Shareholders Equity | $619.43M | $49.06B |
| Retained Earnings | N/A | $47.72B |
| Property, Plant & Equipment | $11.37M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | INMD | ABT |
|---|---|---|
| Operating Cash Flow | $14.14M | $1.42B |
| Capital Expenditures | $-85,000 | $-484.00M |
| Free Cash Flow | $13.96M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | $-99.96M | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | INMD | ABT |
|---|---|---|
| Shares Short | 3.31M | 19.06M |
| Short Ratio | 1.86 | 3.12 |
| Short % of Float | 0.06% | 0.01% |
| Average Daily Volume (10 Day) | 1,222,050 | 5,718,390 |
| Average Daily Volume (90 Day) | 1,557,887 | 7,295,300 |
| Shares Outstanding | 69.56M | 1.73B |
| Float Shares | 53.52M | 1.73B |
| % Held by Insiders | 0.15% | 0.01% |
| % Held by Institutions | 0.71% | 0.81% |
Dividend Analysis & Yield Comparison: InMode vs Abbott Laboratories
| Metric | INMD | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |